Key Insights on Gross Profit: Bio-Techne Corporation vs BioMarin Pharmaceutical Inc.

Biotech Giants' Profit Growth: Bio-Techne vs. BioMarin

__timestampBio-Techne CorporationBioMarin Pharmaceutical Inc.
Wednesday, January 1, 2014251411000621276000
Thursday, January 1, 2015307277000737887000
Friday, January 1, 2016336659000907234000
Sunday, January 1, 20173745410001071860000
Monday, January 1, 20184321430001175948000
Tuesday, January 1, 20194734910001344582000
Wednesday, January 1, 20204831940001336183000
Friday, January 1, 20216328500001375760000
Saturday, January 1, 20227564960001612370000
Sunday, January 1, 20237698150001842161000
Monday, January 1, 20247697250002273680000
Loading chart...

Unleashing insights

A Tale of Two Biotech Giants: Bio-Techne vs. BioMarin

In the ever-evolving world of biotechnology, financial performance is a key indicator of a company's success. Over the past decade, Bio-Techne Corporation and BioMarin Pharmaceutical Inc. have showcased remarkable growth in their gross profits. From 2014 to 2023, Bio-Techne's gross profit surged by over 200%, starting at approximately $251 million and peaking at around $770 million in 2023. Meanwhile, BioMarin's gross profit grew by nearly 200% as well, from about $621 million in 2014 to an impressive $1.84 billion in 2023.

Despite BioMarin's higher absolute figures, both companies have demonstrated consistent upward trends, reflecting their strategic prowess in the biotech sector. Notably, BioMarin's data for 2024 is missing, leaving room for speculation about its future trajectory. As these giants continue to innovate, their financial journeys offer valuable insights into the dynamic landscape of biotechnology.

Published by
U.S. Securities and Exchange Commission

Source link
sec.gov

Date published
17 Jan 2025